Archive for February, 2010

Mandating Mental Health Coverage—a blank check for Psycho/Pharma to get everyone diagnosed mentally ill & drugged

Wednesday, February 3rd, 2010

JBS.org
By Beverly K. Eakman
February 2, 2010

We’ve all heard of “urban sprawl.” But there is another kind of “sprawl” Americans should find more worrisome: legislative sprawl.

Mental health parity is one such example. Government-mandated parity of mental and physical ailments for insurance coverage is a back-door route to nationalized health care. Special interests have been pushing government to implement parity for years and last Friday, January 29, the Obama Administration acquiesced. Health plans will henceforth be required to provide (not merely “offer”) mental-health benefits that contain no zingers, such as separate annual deductibles or lesser rates for psychiatrists and social workers.  Instead, according to Andrew Sperling of the National Alliance on Mental Illness (NAMI), health insurers will be obliged to give the same level of coverage for treatment of emotional angst “as they do for cancer, diabetes and heart disease.” Mental health has morphed into a cottage industry with scores of advocating organizations and lobbyists — NAMI, the American Psychiatric Association, Children and Adults with Attention-Deficit/Hyperactivity Disorders (CHADD), the National Education Association and, of course, pharmaceutical companies. Industry bigwigs have repeatedly insisted that mental-health issues are no different than physical illnesses. The problem is that one cannot verify a mental illness — not with an X-ray, a blood test, a urinalysis or by any other means. Unlike brain injuries, Alzheimer’s and other clear-cut brain impairments due to strokes, high fevers and birth defects, mental illness per se is purely subjective. Perhaps someday researchers will discover issues at the cellular level that definitively cause a certain subset of behaviors, or which exacerbate stress, but at the moment they cannot. So it is no wonder that the various medications and therapies directed at curing, or even alleviating, emotional distress have virtually no track record of success.

Read entire article:  http://www.jbs.org/jbs-news-feed/5917-legislative-sprawl-mandating-mental-health-coverage

« Return to news items


Share

Drug maker AstraZeneca facing 26,000 lawsuits over its antipsychotic drug Seroquel causing diabetes

Wednesday, February 3rd, 2010

Bloomberg.com
By Jef Feeley and Margaret Cronin Fisk
February 3, 2010

AstraZeneca Plc is facing as many as 26,000 lawsuits over its antipsychotic drug Seroquel as the drugmaker prepares for its first jury trial over claims the medicine causes diabetes, according to court filings.

Attorneys for AstraZeneca, the U.K.’s second-largest drugmaker, met with plaintiffs’ lawyers in court-ordered mediation sessions last month to discuss a possible settlement of the Seroquel cases, according to court filings. Consumers’ lawyers said they had about 26,000 cases in their inventories, Stephen Saltzburg, a George Washington University Law School professor who served as mediator, said in the filing.

“I wish there were a magic wand that could be waived to settle all Seroquel cases instantly,” Saltzburg said in the filing. “Such wand does not exist.”

AstraZeneca’s stock fell last week after the drugmaker’s sales forecast and stock-buyback plan disappointed some analysts and fourth-quarter profit missed estimates. The company plans to buy back as much as $1 billion of shares this year, officials said Jan. 28.

The company said in a U.S. Securities and Exchange Commission filing last week it faces more than 25,000 claims that Seroquel caused diabetes.

Read entire article:  http://www.bloomberg.com/apps/news?pid=20601087&sid=a6MfYbj9JtRc&pos=7

That’s a 65 percent increase in cases over the number the company reported in a January 2009 regulatory filing. Many of the suits also claim AstraZeneca promoted Seroquel, approved for schizophrenic and bipolar patients, for unapproved uses.

« Return to news items


Share

In Ireland protests heat up over psychiatrists ability to force unwilling patients to undergo electroshock

Tuesday, February 2nd, 2010

Irish Times
By Carl O’Brien
February 2, 2010

A major debate is unfolding over the use of forced ECTon psychiatric patients

SHOULD A mentally ill patient in distress be forced to undergo electric shock treatment against his or her will?

It’s a question which goes to the heart of a growing debate over one of the most controversial and invasive procedures used in psychiatric care.

Rightly or wrongly, no other treatment arouses as much fear as electroconvulsive therapy (ECT). Depending on who you talk to, ECT is an effective and fast-acting treatment for severe depressive disorders, or it is a potentially dangerous procedure unsupported by research and whose side effects include long-term memory loss.

The growing recognition of patients’ human rights, as well as lobbying by organised advocacy groups, means the issue is now on the political agenda. But the debate is wider than just use of this procedure; it also touches on the key question of just how much power and responsibility should we place in the hands of consultant psychiatrists?

Read entire article:  http://www.irishtimes.com/newspaper/health/2010/0202/1224263563057.html

« Return to news items


Share

Renowned Psycho/Pharma whistleblower Allen Jones speaks out on risks & vindication

Monday, February 1st, 2010

WHYY News and Information
By Kerry Grens
February 1, 2010

Last year, several federal juries in Philadelphia returned the largest ever settlements against drug companies. These lawsuits, which resulted in billions in fines, were spurred by a handful of whistleblowers. WHYY’s Kerry Grens looks at the growing phenomenon of the whistleblower suit.

Allen Jones comes across as …. intense. He lives in a cabin he built in the woods of Snyder County Pennsylvania. He speaks in a very direct and exacting manner. He smokes, and runs his hand through his hair when he gets lost in his thoughts.

Eight years ago, Jones worked as an investigator in Pennsylvania’s Office of the Inspector General.

Jones: An issue landed on my desk involving the state pharmacist Stephen Fiorello.

Jones was asked to look into payments Fiorello had received from pharmaceutical companies. To Jones, it seemed obvious. The payments involved a conflict of interest verging on crime.

Jones: As all of this began to emerge, I began to press my supervisor to broaden the investigation from a personnel issue into a fraud issue and to look more closely at what the drug companies were doing.

Read entire article:  http://whyy.org/cms/news/health-science/2010/02/01/why-people-blow-the-whistle-and-what-they-get-out-of-it/29471

« Return to news items


Share

Antidepressants: The Emperor’s New Drugs? “Depression is not a brain disease, and chemicals don’t cure it.”

Monday, February 1st, 2010

The Huffington Post
By Irving Kirsch, Ph.D.
January 29, 2010

Antidepressants are supposed to be the magic bullet for curing depression. But are they? I used to think so. As a clinical psychologist, I used to refer depressed clients to psychiatric colleagues to have them prescribed. But over the past decade, researchers have uncovered mounting evidence that they are not. It seems that we have been misled. Depression is not a brain disease, and chemicals don’t cure it.

My awareness that the chemical cure of depression is a myth began in 1998, when Guy Sapirstein and I set out to assess the placebo effect in the treatment of depression. Instead of doing a brand new study, we decided to pool the results of previous studies in which placebos had been used to treat depression and analyze them together. What we did is called a meta-analysis, and it is a common technique for making sense of the data when a large number of studies have been done to answer a particular question.

It is rare for a study to focus on the placebo effect–or on the effect of the simple passage of time, for that matter. So where were we to find our placebo data and no-treatment data? We found our placebo data in clinical studies of antidepressants. All told, we analyzed 38 published clinical trials involving more than 3,000 depressed patients. What we found came as a big surprise. It turned out that 75 percent of the antidepressant effect was also produced by placebos – sugar pills with no active ingredients that are used to control the effects of hope and expectation in clinical trials. In other words, most of the improvement seen in patients given antidepressants was a placebo effect.

Read entire article:  http://www.huffingtonpost.com/irving-kirsch-phd/antidepressants-the-emper_b_442205.html

« Return to news items


Share